Genervon Biopharmaceuticals has continued to provide GM604 to Doctors of named ALS patients around the world since our December 10, 2015 Press Release...

Genervon Biopharmaceuticals today announced that its very promising ALS treatment has successfully passed the EM's "COMP" phase. The Committee for Orphan Medicinal Products (COMP) has issued a positive opinion...

Genervon has received many inquiries from ALS patients, caregivers and doctors requesting the access of GM604. The following updated summary is an attempt to answer some of their questions...

PASADENA, Calif. Genervon Biopharmaceuticals ("Genervon") today announced that its lawyers have filed patent for legal protection of its intellectual properties based on the proprietary data from its Phase 2A clinical trial with GM604...

Genervon Biopharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted an "orphan drug" designation to Genervon's GM604 (a.k.a. GM6) bio-drug for the treatment of Amyotrophic Lateral Sclerosis (ALS)...

In a huge victory for ALS sufferers, FDA granted Genervon Biopharmaceuticals a fast track designation for its first in class highly effective multi-target master regulator biotechnology drug GM604 for ALS. FDA said it met the necessary criteria...

Offering imminent hope for those with ALS, Genervon Biopharmaceuticals, an innovative biotechnology company announced today that it has received FDA approval and is now recruiting patients for its broadly inclusive ALS clinical trial...

Multiple targets, highly effective, breakthrough therapy for ALS sufferers may now be within reach. Winston Ko, the CEO of Genervon Biopharmaceuticals, will be presenting on Friday at the Neurotech Conference in San Francisco that its endogenous regulatory drug GM604 modulates over 80 ALS related gene targets interactively and dynamically through 12 pathways and up to 22 biological processes, including neurogenesis, neural development, signaling and transport...